Lumos Pharma — Investor Presentation (November 2023)
57 slides from Lumos Pharma's investor presentation, Nov 15, 2023
Slide 1: Corporate & Clinical Overview November 2023
1 Corporate & Clinical Overview November 2023
Slide 2: Forward Looking Statements
2 Forward Looking Statements This presentation contains forward-looking statements of Lumos Pharma, Inc. that involve substantial risks and uncertainties. All such statements contained in this presentation are forward- looking statements within the meaning of The Private Securities Litigation Reform
Slide 3: Overview
3 Overview Lead asset targeting children with growth disorders Novel Oral Rare Disease Asset Pipeline in a Product Solid Financial Position • Novel oral therapeutic asset, LUM-201, for growth hormone deficiency (GHD) disorders • LUM-201 acts within natural endocrine pathway, differentiated from inje
Slide 4: Management team
4 Richard Hawkins Chairman & CEO Developed Growth Hormone (GH) Receptor Antagonist for Acromegaly at Sensus (sold to Pfizer). Built one of the first contract recombinant protein manufacturing facilities (Covance Biotechnology). Founder of Pharmaco, a pioneer in the contract research organization sec
Slide 5: LUM-201 Program Pipeline
5 LUM-201 Program Pipeline Study Pre-Clinical Phase 1 Phase 2 Phase 3 Status LUM-201 (Ibutamoren) in Moderate PGHD* Dose-finding trial Phase 2 Topline Data: Primary and secondary endpoints met (Nov 2023) Long-term extension Long-term extension study for OraGrowtH Trials: Ongoing enrollment of patien
Slide 6: Pediatric Growth Hormone Deficiency (PGHD) – Conversion from Injection to Oral
6 Pediatric Growth Hormone Deficiency (PGHD) – Conversion from Injection to Oral 1 GlobalData EpiCast Report for Growth Hormone Deficiency Epidemiology forecast to 2026 2 Rosenfeld 2008 Endocrine Practice 3 Cutfield 2011 PLOS ONE Inadequate secretion of growth hormone during childhood • Majority of
Slide 7: Market Research: Daily Oral Therapeutic Preferred Over Weekly Injectable
7 Market Research: Daily Oral Therapeutic Preferred Over Weekly Injectable 1 Initial Primary Research of PGHD Market conducted for Lumos by Triangle Insights. Physicians N = 20. Caregivers N = 9. 75% 25% Interview Question: If a daily oral secretagogue and a weekly rhGH injectable product were both
Slide 8: LUM-201 Stimulates Natural Growth Hormone Secretion
8 LUM-201 Stimulates Natural Growth Hormone Secretion • LUM-201 is an oral GH secretagogue* • Acts on specific receptors in hypothalamus and pituitary to stimulate release of GH1 • Increases the amplitude of natural pulsatile GH secretion, 2,3 normalizing GH levels after 6 months on therapy4 • LUM-2
Slide 9: PEMs Enrich Trials for Patients Likely to Respond to LUM-201
9 PEMs Enrich Trials for Patients Likely to Respond to LUM-201 Responders to LUM-2012 Non-Responders to LUM-201 Moderate PGHD PEM-Positive ~60% of total PGHD population1 Severe PGHD PEM-Negative ~40% of total PGHD population Predictive Enrichment Marker Positive (PEM+) • Baseline IGF-1 > 30 ng/ml •
Slide 10: Post-Hoc Analysis: PEM-Positive Patients Responsive to LUM-201
10 Study 020 Post-Hoc Analysis: PEM-Positive Patients Responsive to LUM-201 • Multiple LUM-201 trials conducted by Merck o In ~1000 adults – for sarcopenia, other • GH/IGF-1 raised from baseline by LUM-201 o In ~200 children – for PGHD • Naïve PGHD, Study 020 o N=68; three arms o Placebo patients sw
Slide 11: PK/PD: Evidence of a PK and PD Dose Response in Healthy Volunteers
11 PK/PD: Evidence of a PK and PD Dose Response in Healthy Volunteers PharmacodynamicsPharmacokinetics Dose response to 5.6 mg/kg PGHD dose equivalent* PD plateau possible ≥ 2.8 mg/kg PGHD dose equivalent* Higher LUM-201 doses produce higher plasma concentrations of LUM-201 & GH up to PD plateau PD
Slide 12: OraGrowtH210 Trial: Phase 2 Trial in Naïve Moderate PGHD
12 OraGrowtH210 Trial: Phase 2 Trial in Naïve Moderate PGHD n = ~20 Daily rhGH injection n = ~20 LUM-201: 3.2 mg/kg/day n = ~20 LUM-201: 1.6 mg/kg/day n = ~20 LUM-201: 0.8 mg/kg/day • n = 82 • PEM(+) PGHD subjects • Inclusion: stim GH ≥ 5 ng/ml and baseline IGF-1 >30 ng/ml • rhGH treatment naïve • ~
Slide 13: OraGrowtH210 Baseline Demographics
13 OraGrowtH210 Baseline Demographics LUM-201 0.8 mg Mean (SD) N=18 LUM-201 1.6 mg Mean (SD) N=22 LUM-201 3.2 mg Mean (SD) N=22 rhGH Mean (SD) N=19 Age (months) 101.3 (29.2) 95.2 (27.3) 94.5 (21.1) 90.7 (23.7) Height (cm) 116.4 (12.4) 113.6 (11.0) 113.8 (9.2) 112.9 (10.7) Height SDS -2.32 (0.30) -2.
Slide 14: OraGrowtH210 Met Primary Statistical Objective: PEM enriches the responder population
14 • PEM test ensures patients enrolled in the study are capable of secreting GH in response to a single-dose of LUM-201 • PEM-positive criteria: o PGHD patients with baseline IGF-1 >30 ng/ml o Peak stimulated GH ≥ 5 ng/ml after a single 0.8 mg/kg dose of LUM-201 no enrich 0.8 PEM 1.6 PEM 3.2 PEM 0
Slide 15: PEM Test Reproducibility
15 PEM Test Reproducibility Subjects with Positive Agreement on PEM Tests 76/76 Reproducibility Rate 100% 95% Confidence Interval (95.3%, 100%) OraGrowtH210 Secondary Statistical Objective: PEM Test Yields Highly Reproducible Results PEM positive classification was 100% reproducible and exceeded pre
Slide 16: OraGrowtH210: 1.6 mg/kg as Optimal Dose for Phase 3
16 OraGrowtH210 Met Primary Objective: 6 and 12-Month AHV Data Support 1.6 mg/kg as Optimal Dose for Phase 3 AHV ANCOVA Model Terms: treatment, Age at dose 1, Sex, Baseline HT SDS, Baseline BMI SDS, Baseline IGF-1 SDS, LUM-201 PEM, Baseline BA Delay, HT SDS-MPH SDS Bars represent Least Squares Mean
Slide 17: Growth Outliers in the rhGH Cohort
17 Age (years) Growth Outliers in the rhGH Cohort: 2 of 3 Subjects under Age 5 Randomized to rhGH 1 Ranke, et al 2010 JCEM OraGrowtH210 youngest subjects in rhGH cohort at 6-months AHV grew well beyond expectations Analysis of Pfizer’s KIGS database of moderate PGHD1: • P lines = Percentiles of expe
Slide 18: LUM-201 Growth Comparable to Multiple 12-Month Historical Datasets
18 LUM-201 Growth Comparable to Multiple 12-Month Historical Datasets *Daily Genotropin control group for Somatrogon Ph3 dosed at 0.034 mg/kg/day (equates to 0.24 mg/kg/wk); subjects were stratified based on GH production during a standard stim test. 1.6 m g/k g 6m 1.6 m g/k g 12 m GeN eS IS iPGHD K
Slide 19: OraGrowtH210 Phase 2: IGF-1 Standard Deviation Score
19 OraGrowtH210 Phase 2: IGF-1 Standard Deviation Score (SDS) LUM-201 Normalizes IGF-1 SDS with Durable Effect out to 12 months baseline 0.8 1.6 3.2 rhGH -2 -1 0 1 2 9 0.74 0.14 -0.21 11 -0.48 41 -1.38 210 IGF-1 SDS 12m data PP12 IG F- 1 SD S mg/kg LUM-201 n=11 n=12 • LUM-201 normalizes IGF-1 within
Slide 20: OraGrowtH210 Summary
20 All primary and secondary endpoints met LUM-201 AHV’s consistent with pre-specified targets from historical benchmarks in moderate PGHD population AHV delta for LUM-201 1.6 mg/kg from comparator daily rhGH arm at 6- and 12-months is within the non-inferiority margin (difference less than 1.8 t
Slide 21: OraGrowtH212 Trial: PK/PD Trial in Naïve Moderate PGHD
21 • n = 22 • Open-label study • Moderate PGHD patients • rhGH-treatment naïve • Dosing to near-adult height • Single, specialized clinical site in Santiago, Chile • Q10 minute GH sampling for 12 hours OraGrowtH212 Trial: PK/PD Trial in Naïve Moderate PGHD Study Endpoints: • Assess LUM-201 effect on
Slide 22: OraGrowtH212 Trial Baseline Demographics
22 OraGrowtH212 Trial Baseline Demographics LUM-201 1.6 mg Mean (SD) N=11 LUM-201 3.2 mg Mean (SD) N=11 Age (months) 99.7 (15.2) 100.9 (21.1) Height (cm) 116.5 (5.5) 116.6 (9.5) Height SDS -2.15 (0.28) -2.26 (0.38) IGF-1 SDS -1.01 (0.64) -0.85 (0.50) MPH (cm) 162.6 (7.0) 160.3 (8.7) MPH SDS ∆ -0.85
Slide 23: OraGrowtH212: Significant Increase in Growth from Baseline AHV at 6 Months
23 OraGrowtH212: Significant Increase in Growth from Baseline AHV at 6 Months • AHV = Annualized Height Velocity • Bars represent sample mean • Error bars represent SEM 1.6 baseline* 1.6 3.2 baseline 3.2 0 5 10 15 11 7.7 11 4.5 11 7.4 10 4.3 6-month AHV A nn ua liz ed H ei gh t V el oc ity (c m /y r
Slide 24: OraGrowtH212 Phase 2: IGF-1 SDS
24 base 1.6 6m 3.2 6m -1.5 -1.0 -0.5 0.0 0.5 1.0 11 0.47 0.14 22 -0.93 IGF-1 SDS - 6m cohort IG F- 1 SD S n=11 base 1.6 12m 3.2 12m -1.5 -1.0 -0.5 0.0 0.5 1.0 7 0.30 -0.03 15 -0.87 IGF-1 SDS - 12m cohort IG F- 1 SD S n=8 • Bars represent sample mean • Error bars represent SEM • Data represent number
Slide 25: OraGrowtH212: LUM-201 Normalizes GH Concentrations in Moderate PGHD
25 Time period Normal healthy (IC-GH‡) Untreated GHD (IC-GH‡) LUM-201 (baseline GH)* LUM-201 (treat 6M GH)* Comparator arm rhGH 34 µg/kg/day Zadik† N = 22 Albertsson- Wikland†† 12h (day) µg/kg.12hr 3.3 + 1.3 1.1 + 0.5 1.3 2.6 - 24h µg/kg/24hr 5.0 + 1.3 1.4 + 0.5 1.7 3.3 – 4.0 ~20 µg/kg/24hr†† Ratio
Slide 26: OraGrowtH212 Summary
26 OraGrowtH212 Summary All primary and secondary endpoints met Increased 6- and 12-month AHV meaningfully from baseline LUM-201 normalized IGF-1 SDS values within 6 months of treatment with durable effect LUM-201 stimulates an increase in pulsatile secretion of GH approximating normal physio
Slide 27: LUM-201 Data Suggests Greater Durability of Response than rhGH to 24 Months
27 AHV values from the OraGrowth studies are based on ANCOVA model (details provided on previous slides) * At 24 months, data include a subset of subjects from OraGrowtH210 trial who met protocol criteria to continue past 12 months. ** Ranke et.al. 2010 – rhGH treated cohort of moderate GHD children
Slide 28: Safety Data from Combined Trials
28 PEM 0.8 mg/kg 1.6 mg/kg 3.2 mg/kg rhGH N =129 N =18 N =33 N=33 N =20 Number of AEs 38 59 155 150 54 Subjects with AE (%) 24 (18.6%) 14 (77.8%) 31 (93.9%) 30 (90.9%) 16 (80.0%) Treatment Related AEs * 7 2 17 20 6 Subjects with Treatment Related AEs (%) 4 (3.1%) 1 (5.6%) 13 (39.4%) 13 (39.4%) 5 (25
Slide 29: Financial Information as of September 30, 2023
29 Lumos Pharma Financial Information as of September 30, 2023 Values in USD Cash, equivalents & short-term investments $42.7M Debt $0 Shares Outstanding 7.9M Cash Use for 4Q 2023 ~ $9.0-$10.0M Fiscal Year End December 31 LUMO Cash, cash equivalents, & short-term investments to support operations th
Slide 30: Recap Summary and Next Steps
30 Recap Summary and Next Steps o Met all primary and secondary endpoints o LUM-201 increases pulsatility, restores GH secretion and normalizes IGF-1 o LUM-201 promotes growth comparable to rhGH with only 20% of GH concentration levels o AHV* delta between optimal 1.6 mg/kg LUM-201 dose and rhGH com
Slide 31: Investment Thesis
31 Investment Thesis Lead asset targeting children with growth disorders Attractive Market Opportunity Novel Asset with Unique MOA Solid Financial Position • Daily oral expected to be well received in GH markets • Market research supports rapid conversation to oral and potential expansion opportunit
Slide 32: Additional Analyses of Phase 2 Data
Additional Analyses of Phase 2 Data
Slide 33: Safety Profile at Interim Analysis for OraGrowtH210 Trial
33 Safety Profile at Interim Analysis for OraGrowtH210 Trial Data cut October 2023 0.8 mg/kg 1.6 mg/kg 3.2 mg/kg ALL LUM-201 rhGH 34 mcg/kg N = 18 22 22 62 20 Number of AEs 59 79 74 212 54 Subjects with AE (%) 14 (77.8%) 20 (90.9%) 19 (86.4%) 53 (85.5%) 16 (80.0%) Treatment Related AEs (N) 2 2 4 8 6
Slide 34: Related OraGrowtH210 Adverse Events
34 Related OraGrowtH210 Adverse Events Preferred Term, N (%) 0.8 N=18 1.6 N=22 3.2 N=22 ALL N=62 rhGH N=20 Comments Contusion -- -- -- -- 1 (5.0) Grade 1, Recovered by next visit Injection Site Bruising -- -- -- -- 2 (10.0) Grade 1, Recovered by next visit Increased Appetite (All Grade 1) 1 (5.6) 1
Slide 35: Serious Adverse Events OraGrowtH210 Trial
35 Serious Adverse Events OraGrowtH210 Trial Serious Adverse Event System Organ Class Gr Study Treatment Relatedness Serious Criteria Product Administration Error Injury, Poisoning and Procedural Complications 1 NA (occurred prior to receiving any study drug) Unrelated Hosp Dehydration Metabolism an
Slide 36: Related OraGrowtH212 AEs
36 Related OraGrowtH212 AEs Preferred Term, N (%) 1.6 N=11 3.2 N=11 ALL N=22 Comments Abdominal Pain 1 (9.1) -- 1 (4.5) Grade 1, Duration: few days Transaminases Increased -- 1 (9.1) 1 (4.5) Grade 1, Duration: <3 months Increased Appetite 11 (100.0) 10 (90.9) 21 (95.5) 19 Grade 1 9 ongoing 10 resolv
Slide 37: Specific OraGrowtH210 AEs – No meaningful signal
37 Specific OraGrowtH210 AEs – No meaningful signal Safety data available for 82 subjects at interim analysis, October 2023 0.8 N=18 1.6 N=22 3.2 N=22 ALL N=62 rhGH N=20 Arthralgia 2 (11.1%) 3 (13.6%) 2 (9.1%) 7 (11.3%) 2 (10.0%) Myalgia 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 3 (15.0%) Headache 5 (27.8
Slide 38: Laboratory Shifts: No meaningful signal
38 Laboratory Shifts: No meaningful signal 82 subjects 0.8 mg/kg N=18 1.6 mg/kg N=22 3.2 mg/kg N=22 ALL N=62 rhGH N=20 ALT Nl to high 2/17 (11.8%) 5/22 (22.7%) 4/22 (18.2%) 11/61 (18%) 7/20 (35%) AST Nl to high 3/14 (21.4%) 4/21 (19%) 5/22 (22.7%) 12/57 (21.1%) 6/20 (30%) Bicarb Nl to high 0/18 (0%)
Slide 39: Laboratory Shifts
39 Laboratory Shifts 0.8 mg/kg N=18 1.6 mg/kg N=22 3.2 mg/kg N=22 ALL N=62 rhGH N=20 Urea nitro Nl to low 4/18 (22.2%) 4/21 (19%) 7/22 (31.8%) 15/61 (24.6%) 7/20 (35%) Urea nitro Nl to high 1/18 (5.6%) 0/22 (0%) 1/22 (4.5%) 2/62 (3.2%) 0/20 (0%) Basophils Nl to high 7/17 (41.2%) 12/22 (54.5%) 10/21
Slide 40: Laboratory Shifts
40 Laboratory Shifts 0.8 mg/kg N=18 1.6 mg/kg N=22 3.2 mg/kg N=22 ALL N=62 rhGH N=20 Globulin Nl to low 6/18 (33.3%) 4/22 (18.2%) 4/22 (18.2%) 14/62 (22.6%) 5/20 (25%) Glucose Nl to high 0/18 (0%) 5/22 (22.7%) 6/22 (27.3%) 11/61 (18%) 0/20 (0%) Glucose Nl to low 0/18 (0%) 0/22 (0.0%) 1/22 (4.5%) 1/6
Slide 41: Laboratory Shifts
41 Laboratory Shifts 0.8 mg/kg N=18 1.6 mg/kg N=22 3.2 mg/kg N=22 ALL N=62 rhGH N=20 Ery. crp. Hb Nl to low 2/17 (11.8%) 2/22 (9.1%) 3/22 (13.6%) 7/61 (11.5%) 2/20 (10%) Ery. crp. vol Nl to low 1/18 (5.6%) 3/21 (14.3%) 3/22 (13.6%) 7/61 (11.5%) 1/20 (5%) Ery. crp vol Nl to high 0/17 (0.0%) 0/22 (0.0
Slide 42: Laboratory Shifts: No meaningful signal
42 Laboratory Shifts: No meaningful signal 0.8 mg/kg N=18 1.6 mg/kg N=22 3.2 mg/kg N=22 ALL N=62 rhGH N=20 Eryth. Nl to high 1/17 (5.9%) 2/22 (9.1%) 2/22 (9.1%) 5/61 (8.2%) 1/20 (5%) Eryth. Nl to low 1/18 (5.6%) 0/22 (0.0%) 0/22 (0.0%) 1/62 (1.6%) 0/20 (0%) Leukocyt. Nl to high 1/17 (5.9%) 2/22 (9.1
Slide 43: Supplementary Materials
Supplementary Materials
Slide 44: Historical Data Show LUM-201 Augments GH Pulsatility and Increases Circulating IGF-1
44 Historical Data Show LUM-201 Augments Growth Hormone (GH) Pulsatility and Increases Circulating IGF-1 • Adults with GH deficiency • Individual subjects • Representative 24-hour GH profiles on Day 4 of treatment Chapman 1997 J Clin Endocrinol Baseline 10 mg, Day 4 50 mg, Day 4
Slide 45: Historical Data Demonstrate Differentiated MOA of LUM-201 vs rhGH
45 Historical Data Demonstrate Differentiated MOA of LUM-201 vs rhGH LUM-201 Augments Growth Hormone (GH) Pulsatility in GHD Adults • Adults with GH deficiency • LUM-201 augments endogenous GH pulses • rhGH is administered as single, daily bolus doses 1 Adapted, Chapman 1997 J Clin Endocrinol 2 Jans
Slide 46: Historical Data Show LUM-201 Effects Are Durable in Healthy Elderly
46 Historical Data Show LUM-201 Effects Are Durable in Healthy Elderly Nass 2008 Ann Intern Med LUM-201 mediated increases in serum GH and IGF-1 are sustained over 1 year of treatment
Slide 47: Interim OraGrowtH210 Data (November 2022): rhGH Cohort Grew More than Historical Norms
47 Interim OraGrowtH210 Data (November 2022): rhGH Cohort Grew More than Historical Norms in Moderate PGHD Patient Population Unprecedented rhGH growth response in OraGrowtH 210 in moderate PGHD at ~50% enrollment likely due to outlier & small sample size Expect larger N from fully enrolled OraGrowt
Slide 48: OraGrowtH212 Trial: Pulsatility and AHV data: Patient A
48 Cassorla, F, et al. IMPE, March 2023 OraGrowtH212 Trial: Pulsatility and AHV data: Month 6 for Patient A (1.6 mg/kg/day) From interim data, November 2022 Baseline 6 months LUM-201 3.2 mg/kg/d IGF-1 (ng/ml) 179 289 % change from baseline** 61% Q10m 12h GH AUC0-12 (ng*hr/ml) 798.8 1064.1 % change f
Slide 49: OraGrowtH212 Trial: Pulsatility and AHV data: Patient B
49 Cassorla, F, et al. IMPE, March 2023 0 200 400 600 800 0 1 2 3 4 5 Patient B Time (min) Se ru m G ro w th H or m on e (n g/ m l) Baseline Month 6 Patient B Serum GH at Baseline & at 6 months on LUM-201 OraGrowtH212 Trial: Pulsatility and AHV data: Month 6 for Patient B (3.2 mg/kg/day) From interi
Slide 50: OraGrowtH212 Trial: Change from Baseline in Mean GH Concentration and GH AUC
50 OraGrowtH212 Trial: Change from Baseline in Mean GH Concentration and GH AUC0-12h after 6-months LUM-201 Daily Dosing at ~70% Enrollment (N=15) Dose of LUM-201 1.6 mg/kg (n = 8) 3.2 mg/kg (n=7) baseline 6 mo baseline 6 mo mean GH conc (ng/ml) Median 1.04 1.22 0.47 1.36 95% CI 0.51-1.59 0.81-1.93
Slide 51: Key Baseline Characteristics that Predict Better AHV With rhGH Treatment
51 Key Baseline Characteristics that Predict Better AHV With rhGH Treatment of PGHD Patients Historical data from multiple peer-reviewed scientific publications demonstrate the following metrics as key predictors of first-year growth • Baseline Age • Age is the top predictor of growth on treatment •
Slide 52: Ranke Model is the Gold Standard in Growth Prediction for GHD
52 Ranke Model is the Gold Standard in Growth Prediction for GHD PHV = 14.55 + [-1.37 X (ln max GH stim)] + (-0.32 X Age) + (0.32 X BWt SDS) + (-0.5457) + (-0.4 X HtSDS-MPH SDS) + (0.29 X Wt SDS) [-1.37 X (ln max GH stim)]• Parameter Rank 1st A measure of how GHD subject is by stim test value (-0.32
Slide 53: PGHD is ~35% of the $3.4B Pediatric Recombinant Growth Hormone Market
53 PGHD is ~35% of the $3.4B Pediatric Recombinant Growth Hormone Market • Pediatric rhGH market projected to grow ~8% per year* • Well characterized market with established reimbursement mechanisms • Current SOC consists of daily injectables; expected to convert to weekly injectables • Pediatric rh
Slide 54: Growth Hormone Deficiency Patients Have a Range of Secretion Insufficiency
54 Growth Hormone Deficiency Patients Have a Range of Secretion Insufficiency • Well established in the literature: o A wide range of severity in GHD1 o Variability in responses to GH therapy o Severely GH deficient patients exhibit greater growth response to rhGH compared to moderately deficient pa
Slide 55: PEM Segmentation Aligns With Patients’ Differentiated Baseline Characteristics
55 PEM Segmentation Aligns With Patients’ Differentiated Baseline Characteristics PEM Predictive Enrichment Marker SDS Standard Deviation Score 1 Blum 2021 JES; mean growth after 1 year of treatment 2 Bright 2021 JES Severe 38% Moderate 62% GeNeSIS1 12,315 GHD 514 isolated GHD Baseline Chronological
Slide 56: More GH Released from LUM-201 Stim than from Standard Stim Test Agents
56 More GH Released from LUM-201 Stim than from Standard Stim Test Agents 0 2 4 6 8 10 12 GH to Standard GH Stimulation Tests (ng/mL) 2 4 6 8 20 40 60 80 G H to S in gl e D os e LU M -2 01 (n g/ m L) 68 children with growth hormone deficiency All had 2 standard GH stimulation tests • Standard test a
Slide 57: Study of Oral LUM-201 in Non-Alcoholic Fatty Liver Disease (NAFLD)
57 • n = 10 • Adult NAFLD subjects with relative GH/IGF-1 deficiency • Open-label • Single-site pilot study • 6-month dosing Study of Oral LUM-201 in Non-Alcoholic Fatty Liver Disease (NAFLD) Mass General Investigator-Initiated Phase 2 Pilot Trial Primary Objective: • Determine changes in intra- hep